Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Author(s): Valentina Echeverria*, George E. Barreto, Marco Avila-Rodriguezc, Vadim V. Tarasov , Gjumrakch Aliev*.

Journal Name: Current Alzheimer Research

Volume 14 , Issue 11 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Background: The vascular endothelial growth factor (VEGF) is a neuroprotective cytokine that promotes neurogenesis and angiogenesis in the brain. In animal models, it has been shown that environmental enrichment and exercise, two non-pharmacological interventions that are beneficial decreasing the progression of Alzheimer disease (AD) and depressive-like behavior, enhance hippocampal VEGF expression and neurogenesis. Furthermore, the stimulation of VEGF expression promotes neurotransmission and synaptic plasticity processes such as neurogenesis. It is thought that these VEGF actions in the brain, may underly its beneficial therapeutic effects against psychiatric and other neurological conditions.

Conclusion: In this review, evidence linking VEGF deficit with the development of AD as well as the potential role of VEGF signaling as a therapeutic target for cotinine and other interventions in neurodegenerative conditions are discussed.

Keywords: VEGF, Alzheimer disease, amyotrophic lateral sclerosis, cotinine, nicotinic receptors, depression, tobacco, angiogenesis, dementia, neurodegeneration.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1155 - 1163]
Pages: 9
DOI: 10.2174/1567205014666170329113007
Price: $58

Article Metrics

PDF: 40